Healthcare

Companion Diagnostics: Biomarker Platforms Enabling Precision Medicine

Unveiling One of the Most Promising Fields of Therapeutic Technology Synergy

INDUSTRY
Healthcare

RELEASE DATE
13-Nov-2018
REGION
Global
DELIVERABLE TYPE
Technology Research

RESEARCH CODE
D83E-01-00-00-00
SKU
HC03104-GL-TR_22527
Yes
SHARE

Companion Diagnostics: Biomarker Platforms Enabling Precision Medicine
Published on: 13-Nov-2018 | SKU: HC03104-GL-TR_22527

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

Both predictive and prognostic biomarkers constitutes an central element in each and every targeted oncology drug discovery and development program. Breakthrough technologies allowing leveraging biomarkers for oncology are paving the way of personalized medicine and precision oncology. Indeed, oncology biomarkers provide the clinical community with the opportunity to offer individualized therapies and health programs. Furthermore, oncology biomarkers enable to get critical information about the mechanism of action of a drug or target, to profoundly study carcinogenesis process, and to match patient characteristics specifically to the most appropriate treatment.

1.1 Companion Diagnostics: The Bigger Picture

1.2 Research Focus: Advancing New Diagnostics and Therapeutics

1.3 Research Scope: Unveiling Novel Diagnostics Pathways

1.4 Analysis Framework: Frost & Sullivan’s Core Value

1.5 Research Methodology: Five Steps toward Success

2.1 Key Elements of Analysis: The ‘Companion Diagnostics’ Concept

2.2 Brief Overview of Companion Diagnostics

2.3 Effectiveness and Performance Validation for CDx

2.4 Overall Landscape of Cancer Companion Diagnostics

2.5 Precision Oncology Accelerated Pathway

2.6 Biomarker Stratification for Companion Diagnostics

2.7 Emerging Opportunities for Companion Diagnostics

3.1 Technology Synergy Reshaping Value Chain

3.2 Product Development and Commercialization

3.3 Technology and Business Landscape: Accelerators

3.4 Technology and Business Landscape: Challenges

3.5 New Approaches Driving Companion Diagnostics Solutions

4.1 Market Dynamics and Opportunities

4.2 Market Potential: Technology Focus Segmentation

4.3 Market Potential: Therapeutic Area and Regional Segmentation

4.4 Impact of Companion Diagnostics on Therapeutic Areas

4.5 Prominent Pharmaceutical Market Leaders

5.1 The Role of Stakeholders in Business Strategy

5.2 Technology Transfer Assessment and Perceptions

5.3 Disruptive Companion Diagnostics Solutions

5.4 Business Model Hybridization

5.5 Overall Environmental Impact Factors

5.6 Future Perspective for Companion Diagnostics

6.1 Key Funding and Investment Opportunities

6.2 Funding and Investment Models and Adoption

6.3 Funding Long Shots, Securitization, and Credit

6.4 Strategic Collaborations

7.1 Multicriteria Approach for Benchmarking

7.2 Strategic Portfolio Assessment

7.3 Level 1 Criteria: Innovation Development

7.4 Level 1 Criteria: Financial Performance

7.5 Level 1 Criteria: Market Evolution

7.6 Level 2 Criteria: Key Actions for Success

7.7 Analytic Performance Results

7.8 Multicriteria Final Assessment

7.9 Strategic Imperatives: Critical Success Factors

8.1 Key Industry Influencers

8.1 Key Industry Influencers (continued)

8.1 Key Industry Influencers (continued)

8.1 Key Industry Influencers (continued)

8.1 Key Industry Influencers (continued)

Legal Disclaimer


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

19 Nov 2026   |   Global   |   Technology Research

Programmable Vaccines: AI-Designed Antigens and Next-Generation Rapid Platforms

Traditional vaccine development is an empirical, time-consuming process that often leads to a high failure rate. With the proven clinical success of RNA vaccines, there has been a focus on accelerating the development of vaccines to address the growing incidence of infectious diseases and emerging p...

17 Nov 2026   |   Global   |   Frost Radar

Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026

Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...

16 Nov 2026   |   North America   |   Frost Radar

Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026

This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...

03 Nov 2026   |   North America   |   Market Research

Enterprise Imaging Market, United States, 2025–2030

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...

02 Nov 2026   |   Global   |   Market Research

Continuous Glucose Monitoring Market, Global, 2026

The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.